Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATF4 | P18848 | 12/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25814872 | 0.94 | KMT2A (0.41) | MEN1KMT2AATF4RXFP1 | |
| SCHEMBL22956184 | 0.92 | ALDH1A1 (0.43) | MEN1KMT2AATF4ITGB3ITGA2B | |
| SCHEMBL22956261 | 0.89 | MEN1 (0.40) | MEN1KMT2AATF4RXFP1 | |
| SCHEMBL22956383 | 0.89 | HDAC3 (0.40) | MEN1KMT2AATF4RXFP1 | |
| SCHEMBL25814790 | 0.88 | ATF4 (0.40) | MEN1KMT2AATF4RXFP1 | |
| SCHEMBL25819800 | 0.88 | ATF4 (0.45) | ATF4 | |
| SCHEMBL22627886 | 0.88 | ATF4 (0.41) | MEN1KMT2AATF4 | |
| SCHEMBL25809989 | 0.87 | MEN1 (0.40) | MEN1KMT2AATF4RXFP1 | |
| SCHEMBL22956480 | 0.86 | ATF4 (0.44) | ATF4 | |
| SCHEMBL22956176 | 0.85 | ALDH1A1 (0.39) | MEN1KMT2AATF4RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913727-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | MEN1 4714/4885KMT2A 4320/4885ATF4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.